E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Gilead Sciences's adjusted earnings per share data for the three months ended in Dec. 2023 was $1.140. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $6.61 for the trailing ten years ended in Dec. 2023.
During the past 12 months, Gilead Sciences's average E10 Growth Rate was 6.80% per year.
During the past 3 years, the average E10 Growth Rate was 9.50% per year.
During the past 5 years, the average E10 Growth Rate was 6.70% per year.
During the past 10 years, the average E10 Growth Rate was 16.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.
During the past 13 years, the highest 3-Year average E10 Growth Rate of Gilead Sciences was 85.40% per year. The lowest was 4.50% per year. And the median was 31.65% per year.
As of today (2024-04-25), Gilead Sciences's current stock price is $67.08. Gilead Sciences's E10 for the quarter that ended in Dec. 2023 was $6.61. Gilead Sciences's Shiller PE Ratio of today is 10.15.
During the past 13 years, the highestShiller PE Ratio of Gilead Sciences was 77.37. The lowest was 9.93. And the median was 14.99.
Gilead Sciences E10 Historical Data
The historical data trend for Gilead Sciences's E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Gilead Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences's Shiller PE Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's Shiller PE Ratio falls into.
Gilead Sciences E10 Calculation
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Gilead Sciences's adjusted earnings per share data for the three months ended in Dec. 2023 was:
Add all the adjusted EPS together and divide 10 will get our e10.
Gilead Sciences (NAS:GILD) E10 Explanation
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Gilead Sciences's Shiller P/E Ratio of today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
During the past 13 years, the highest Shiller P/E Ratio of Gilead Sciences was 77.37. The lowest was 9.93. And the median was 14.99.
Be Aware
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
Gilead Sciences E10 Related Terms
Thank you for viewing the detailed overview of Gilead Sciences's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences (Gilead Sciences) Business Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GILD has been successfully added to your 